Chronic hepatitis C in HIV-infected individuals

AIDS Reviews

Volumn 2, Issue 3, 2000, Pages 168-177

  Torriani, F J ^a   Soriano, V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HAART; Hepatitis C virus; Hepatotoxicity; HIV; Interferon; Liver disease; Ribavirin

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; INTERFERON; NEVIRAPINE; PROTEINASE INHIBITOR; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

BLOOD TOXICITY; CLINICAL TRIAL; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MECHANISM; HEALTH CARE AVAILABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TOXICITY; MORBIDITY; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PREVALENCE; REVIEW; VIRUS TRANSMISSION;

EID: 0034541152     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Hepatitis C: Global prevalence
2. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
3. The natural history of hepatitis C virus infection
4. Epidemiology of hepatitis C
5. Hepatitis C
6. Hepatitis C and HIV infection: Biological, clinical, and therapeutic implications
7. HIV infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
8. Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients
9. Hepatitis C virus/human immunodeficiency virus coinfection: Clinical management issues
10. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with HAART
11. Elevated liver enzymes in patients on protease inhibitors with and without markers for hepatitis: Results from the CHORUS observational database
12. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
13. Liver damage and kinetics of hepatitis C virus and HIV replication during the early phases of combination antiretroviral treatment
14. Mortality for liver disease in patients with HIV infection: A cohort study
15. Management of chronic hepatitis C in HIV infected patients
16. Variability of hepatitis C virus
17. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C
18. Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: Comparison of second and third generation anti-HCV testing
19. Hepatitis C virus infection in patients infected with the HIV
20. Prevalence of antibody to hepatitis C virus in HIV-1 infected patients
21. The influence of hepatitis C on the prognosis of HIV: The EuroSIDA Study
22. Correlates of hepatitis C virus infections among drug users
23. Coinfection of hepatitis C virus with HIV and progression to AIDS
24. The association between hepatitis C virus genotype and HIV disease progression in a cohort of hemophilic men
25. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients
26. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
27. Influence of hepatitis C virus genotypes and HIV infections on histological severity of chronic hepatitis C
28. Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators
29. Effect of antiretroviral therapy and prophylaxis against opportunistic diseases on survival of patients with AIDS
30. Rapidly progressive non-A, non-B hepatitis in patients with HIV infection
31. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with HIV. The Multicenter Hemophilia Cohort Study
32. The progression of HCV-associated liver disease in a cohort of haemophilic patients
33. Influence of HIV-1 on the natural course of chronic parenterally acquired hepatitis C
34. Hepatitis C virus is related to progressive liver disease in HIV-positive hemophiliacs and should be treated as an opportunistic infection
35. Increasing mortality from end-stage liver disease secondary to hepatitis C in patients with HIV
36. Natural history of liver fibrosis progression in patients with chronic hepatitis C
37. Which patients with Hepatitis C develop liver complications?
38. Immunity to hepatitis C virus. A further piece of the puzzle
39. Immunologic responses to HCV and non-HCV antigens in HIV-infected and HIV/HCV co-infected patients
40. HCV quasispecies as a mechanism of rapidly progressive liver disease in patients infected with HIV
41. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C
42. Change in transaminases in HCV and HIV coinfected patients after HAART: Differences between complete and partial virologic responders?
43. Impact of treatment with HIV protease inhibitors on hepatitis C viremia in patients coinfected with HIV
44. Hepatocarcinoma in HIV-HCV coinfected patients
45. Randomised trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
46. Negative impact of HCV infection on HIV progression, survival and immune restoration in the Swiss HIV cohort studies
47. Hepatotoxicity after introduction of highly active antiretroviral therapy
48. Severe hepatitis cytolysis: Incidence and risk factors in patients treated with antiretroviral combinations (Aquitaine Cohort, France 1996-1998)
49. Hepatotoxicity associated with antiretroviral therapy in adults with HIV and the role of hepatitis B or C infection
50. Acute hepatitis in HIV-infected patients during ritonavir treatment
51. Hepatitis C virus associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
52. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
53. Rapidly evolving hepatitis C virus-related cirrhosis in a HIV-infected patient receiving triple antiretroviral therapy
54. Consensus Development Conference Panel Statement: Management of hepatitis C
55. Consensus statement: EASL International Consensus Conference on hepatitis C
56. CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C
57. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy
58. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
59. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
60. Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
61. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
62. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover
63. Combination therapy with peginterferon a-2a (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC): A phase II open-label study
64. The pharmacokinetics of pegylated-40K interferon alfa-2a (PEF-IFN) in chronic hepatitis C (CHC) patients with cirrhosis
65. Efficacy and safety of peg (40kDa) IFNa-2a qw in patients with chronic hepatitis C with compensated cirrhosis
66. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to HIV. Comité des Anti-Viraux
67. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients
68. Hepatitis C virus viremia in HIV-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay
69. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. The Hepatitis-HIV Spanish Study Group
70. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count
71. Interferon alfacon-1 (Infergen) treatment for prior interferon alfa-2A or 2B non-responders coinfected with hepatitis C virus and HIV
72. A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients
73. Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C
74. Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
75. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment
76. Interferon plus ribavirin in HCV/HIV coinfected patients
77. Sustained virologic response following interferon and ribavirin therapy for hepatitis C patients who are co-infected with HIV
78. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis/HIV Spanish Study Group